Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 15/20 | 0.36 |
| ▸ | BCHE | P06276 | 6/20 | 0.36 |
| ▸ | CNR1 | P21554 | 4/20 | 0.35 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.35 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.35 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | ACHE | P22303 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6372106 | 0.81 | KDM4E (0.41) | CNR2BCHECNR1OPRM1ALOX5AP | |
| SCHEMBL6241391 | 0.81 | MEN1 (0.46) | CNR2BCHECYP3A4ACHE | |
| SCHEMBL6244070 | 0.79 | CYP3A4 (0.55) | CNR2BCHECNR1ALOX5APS1PR1 | |
| SCHEMBL6245661 | 0.76 | ALOX5AP (0.42) | CNR2BCHECNR1ALOX5APACHE | |
| SCHEMBL6247536 | 0.76 | CNR2 (0.37) | CNR2BCHEALOX5APS1PR1ACHE | |
| SCHEMBL6498532 | 0.75 | AAK1 (0.34) | S1PR1 | |
| SCHEMBL6243895 | 0.74 | TSHR (0.45) | CNR2BCHEALOX5APACHE | |
| SCHEMBL6216622 | 0.71 | ALOX5AP (0.37) | CNR2ALOX5APS1PR1 | |
| SCHEMBL6500097 | 0.71 | CNR2 (0.42) | CNR2BCHECYP3A4ACHE | |
| SCHEMBL3731009 | 0.71 | CNR2 (0.47) | CNR2BCHECNR1OPRM1ALOX5AP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6919331-B2 | Substituted 2-methyl-benzimidazole respiratory syncytial virus antiviral agents | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-07-19 | — | — | US | disclosed |
| US-20030207868-A1 | Substituted 2-methyl-benzimidazole respiratory syncytial virus antiviral agents | BRISTOL-MYERS SQUIBB COMPANY | 2003-11-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030207868-A1 | Substituted 2-methyl-benzimidazole respiratory syncytial virus antiviral agents | MAVS, ZC3HAV1, EIF2AK2 | CNR2 4156/4885BCHE 3508/4885CNR1 4063/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.